IP Library Granted Patent US 10,793,504
Granted Patent B2
US 10,793,504 · App. 16/326,909 · Granted Oct 6, 2020

Methods for cross coupling

Inventors: Joseph Robert Pinchman (San Diego, CA); Chad Daniel Hopkins (San Diego, CA); Kevin Duane Bunker (Escondido, CA); Peter Qinhua Huang (San Diego, CA)
Assignee: Recurium IP Holdings, LLC
C07C67/343B01J31/22C07D213/26C07D239/26C07D263/56C07D413/08C07F5/02C07F5/025B01J2531/821B01J2531/824B01J2531/847C07C2602/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,793,504
App. No.
16/326,909
Granted
Oct 6, 2020
Kind
B2
Abstract

Methods of preparing substituted bicyclo[0.1.1.1]pentane compounds of Formula (I) comprise reacting a compound of Formula (A) with a compound of Formula (B) in the presence of a first transition metal catalyst selected from a palladium catalyst and a nickel catalyst, where the variables R 1 , R 2 , X 1 and X 2 are as described herein.

Claims (54)

1. A method for preparing a substituted bicyclo[1.1.1]pentane compound of Formula (I), comprising:

reacting a compound of Formula (A) with a compound of Formula (B) in the presence of a first transition metal catalyst, optionally a second transition metal catalyst, and optionally a base, under conditions selected to form a compound of Formula (I);

wherein the compound of Formula (A) has the structure:

wherein R 1 is selected from the group consisting of hydrogen, an optionally substituted C 1-30 alkyl, an optionally substituted C 2-30 alkenyl, an optionally substituted C 3-10 monocyclic cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, a halogen, an optionally substituted C-carboxy, an amino, a mono-substituted amino, a di-substituted amino, an optionally substituted C-amido, an optionally substituted N-amido, an optionally substituted C 1-30 alkoxy, a hydroxy, an optionally substituted C 1-30 haloalkyl, a cyano, an optionally substituted S-sulfonamido, an optionally substituted N-sulfonamido, an optionally substituted O-carboxy, an optionally substituted C 2-30 alkynyl, an optionally substituted C 3-10 cycloalkenyl, an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl), an optionally substituted acyl, an optionally substituted thiocarbonyl, an optionally substituted O-carbamyl, an optionally substituted N-carbamyl, an optionally substituted O-thiocarbamyl, an optionally substituted N-thiocarbamyl, an optionally substituted C-thioamido, an optionally substituted N-thioamido, an optionally substituted sulfenyl, an optionally substituted sulfinyl, an optionally substituted sulfonyl, an optionally substituted haloalkoxy, and a first boron-containing moiety, wherein the first boron-containing moiety is connected by the boron;

wherein the first boron-containing moiety is selected from the group consisting of an organoborane, a boronic ester, a boronic acid, a trifluoroborate salt, an N-coordinated boronate, a boronate and a boronamide;

wherein X 1 is selected from the group consisting of a —C(═O)Y, and a second boron-containing moiety;

wherein the second boron-containing moiety is selected from the group consisting of an organoborane, a boronic ester, a boronic acid, a trifluoroborate salt, an N-coordinated boronate, a boronate and a boronamide, wherein the second boron-containing moiety is connected by the boron;

wherein the compound of Formula (B) has the structure R 2 —X 2 ;

wherein R 2 is selected from the group consisting of an optionally substituted C 1-30 alkyl, an optionally substituted C 2-30 alkenyl, an optionally substituted C 3-10 cycloalkyl, an optionally substituted C 3-10 cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

wherein X 2 is selected from the group consisting of a halide, a pseudohalide, a —C(═O)Y, a zinc halide, a zinc pseudohalide, a magnesium halide, a magnesium pseudohalide and a third boron-containing moiety selected from the group consisting of an organoborane, a boronic ester, a boronic acid, a trifluoroborate salt, an N-coordinated boronate, a boronate and a boronamide;

wherein the first transition metal catalyst is selected from the group consisting of a Pd catalyst and a Ni catalyst;

wherein the second transition metal catalyst is selected from the group consisting of an Ir catalyst, a Cu catalyst and an Ru catalyst;

wherein the compound of Formula (I) has the structure:

wherein the bond between R 2 and the bicyclo[1.1.1]pentane in the compound of Formula (I) is a carbon-carbon bond;

wherein each Y is independently selected from the group consisting of a halide, an optionally substituted heterocyclyl, an optionally substituted heteroaryl, SR 6 , OR 6 , SM and OM;

wherein each R 6 is independently selected from the group consisting of a hydrogen, an optionally substituted C 1-30 alkyl, an optionally substituted C 2-30 alkenyl, an optionally substituted C 3-30 cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heteroaryl, and an optionally substituted aryl; and

wherein each M is independently selected from the group consisting of a monovalent cation and a divalent cation;

provided that at least one of X 1 and X 2 is not a boron-containing moiety; and

provided that when the second transition metal catalyst is present, either X 1 or X 2 is a —C(═O)Y.

2. The method of claim 1 , wherein the first transition metal catalyst is selected to undergo oxidative addition to the compound of Formula (A) or the compound of Formula (B).

3. The method of claim 2 , wherein the first transition metal catalyst is a Pd catalyst comprising a Pd atom.

4. The method of claim 2 , wherein the first transition metal catalyst is a Ni catalyst comprising a Ni atom.

5. The method of claim 1 , wherein the first transition catalyst is selected from the group consisting of PdCl 2 , Pd(ACN) 2 Cl 2 , Pd(benzonitrile) 2 Cl 2 , Pd(1,5-COD)Cl 2 , allylpalladium chloride dimer, Pd(dba) 2 , Pd 2 (dba) 3 , Pd(OAc) 2 , Pd(AmPhos) 2 , Pd(P(tBu) 3 ) 2 , Pd(AmPhos) 2 Cl 2 , Pd(P(o-tolyl) 3 ) 2 , Pd(PPh 3 ) 4 , Pd(QPhos) 2 , PdCl 2 (dtbpf), Pd(PCy 3 ) 2 , bis(di-t-butyl-phenylphosphine)Pd(Cl) 2 , PdCl 2 (PPh 3 ) 4 , PdCl 2 (dppf), Chloro {2-[1-(N-methoxy)iminoethyl]phenyl}{[1,3-bis(2,6-di-i-propylphenyl]imidzole-2-ylidene}palladium(II), Chloro {2-[(1-(N-phenyl)iminoethyl[phenyl}{[1,3-bis(2,6-di-i-propylphenyl]imidzole-2-ylidene}palladium(II), Methanesulfonato(1,1-bis(di-t-butylphosphino)ferrocene)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-di-t-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-tri-i-propylbiphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Allyl(cyclopentadienyl)palladium(II), Methanesulfonato(2-di-t-butylphosphino-1,1′-binaphthyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Di-MU-iodobis(tri-t-butylphosphino)dipalladium(I), Methanesulfonato[2-diethylphosphino-2′,6′-bis(dimethylamino)-1,1-biphenyl](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Acetato(2′-di-t-butylphosphino-1,1′-biphenyl-2-yl)palladium(II), Acetato(2,9-dimethyl-1,10-phenanthroline)palladium(II) dimer bis(trifluoromethanesulfonate), Allylchloro[1,3-bis(2,6-di-i-propylphenyl)-4,5-dihydroimidazol-2-ylidene]palladium(II), Allylchloro[1,3-bis(2,6-di-i-propylphenyl)imidazol-2-ylidene]palladium(II), Allylchloro[1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene]palladium(II), trans-Bis(dicyclohexylamine)bis(acetato)palladium(II), Bis {[4-(N,N-dimethylamino)phenyl]di-t-butylphosphino}palladium(0), N,N′-[Bis(2,6-dimethylphenyl)-1,3-dimethyl-1,3-propanediylidene](methyl) (triethylphosphine)palladium(II), [1,3-Bis(2,6-di-i-propylphenyl)-4,5-dihydroimidazol-2-ylidene]{2-[(dimethylamino-kN)methyl]phenyl-kC}(pyridine)palladium(II) tetrafluoroborate, 1,3-Bis(2,6-di-i-propylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium(0), [P,P′-1,3-Bis(di-i-propylphosphino)propane][P-1,3-bis(di-i-propylphosphino)propane]palladium(0), 1,2-Bis(phenylsulfinyl)ethanepalladium(II) acetate, Bis(tri-t-butylphosphine)palladium(0), [1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene]{2-[(dimethylamino-kN)methyl]phenyl-kC}(pyridine)palladium (II) tetrafluoroborate, 1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium(0) dimer, Bis(tri-o-tolylphosphine)palladium(0), Chloro(1-t-butylindenyl) [1,3-bis(2,6-di-i-propylphenyl)imidazol-2-yl]palladium(II), Chloro(1-t-butylindenyl)[2-(dicyclohexylphosphino)-2′,6′-dimethoxy-1,1′-biphenyl]palladium(II), Chloro(1-t-butylindenyl) [2-(dicyclohexylphosphino)-2′,6′-di-i-propoxy-1,1′-biphenyl]palladium(II), Chloro(1-t-butylindenyl) [2-(dicyclohexylphosphino)-2′,4′,6′-tri-i-propyl-1,1′-biphenyl]palladium(II), Chloro(1-t-butylindenyl)palladium(II) dimer, Chloro(2-di-t-butylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl) [2-(2-aminoethyl)phenyl]palladium(II), Chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II), Chloro(2-dicyclohexylphosphino-3,6-dimethoxy-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-tri-i-propyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl]palladium(II), Chloro[2-(dicyclohexylphosphino)-2′-(N,N-dimethylamino)-1,1′-biphenyl[(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Chloro(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Chloro(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl) [2-(2-aminoethylphenyl)]palladium(II), Chloro(2-dicyclohexylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl) palladium(II), Chloro(2-dicyclohexylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II), Chloro{[4-(N,N-dimethylamino)phenyl]di-t-butylphosphino}(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Chloro[9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene][2′-amino-1,1′-biphenyl]palladium(II), Chloro(di-2-norbornylphosphino)(2′-dimethylamino-1,1′-biphenyl-2-yl)palladium(II), Chloro(di-2-norbornylphosphino)(2-dimethylaminomethylferrocen-1-yl)palladium(II), Chloro[(1,2,3-η)-1-phenyl-2-propen-1-yl]-{[1,3-bis[2,6-bis(diphenylmethyl)-4-methylphenyl]-2H-imidazol-2-ylidene}palladium(II), Chloro[(1,2,3-η)-3-phenyl-2-propenyl][1,3-bis(2,6-di-i-propylphenyl)-4,5-dihydroimidazol-2-ylidene]palladium(II), Chloro[(1,2,3-η)-3-phenyl-2-propenyl][1,3-bis(2,6-di-i-propylphenyl)imidazol-2-ylidene]palladium(II), Chloro(tri-t-butylphosphine)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Diacetato[1,3-bis(diphenylphosphino)propane]palladium(II), trans-Di(μ-acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II), Di-μ-bromobis(tri-t-butylphosphino)dipalladium(I), Dichlorobis(acetonitrile)palladium(II), Dichlorobis(benzonitrile)palladium(II), Dichlorobis(di-t-butylphenylphosphino)palladium(II), Dichloro[1,1′-bis(dicyclohexylphosphino)ferrocene]palladium(II), Dichloro[(R)-(+)-2,2′-bis(di-2-furanylphosphino)-6,6′-dimethoxy-1,1′-biphenyl]palladium(II), Dichlorobis{[4-(N,N-dimethylamino)phenyl]di-t-butylphosphino}palladium(II), Dichloro[(R)-(+)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl]palladium(II), Dichloro[(S)-(−)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl]palladium(II), Dichloro[1,4-bis(diphenylphosphino)butane]palladium(II), Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II), Dichloro{bis[2-(diphenylphosphino)phenyl]ether}palladium(II), Dichloro[1,1′-bis(di-i-propylphosphino)ferrocene]palladium(II), trans-Dichlorobis(triphenylphosphine)palladium(II), Dichloro(di-μ-chloro)bis[1,3-bis(2,6-di-i-propylphenyl)imidazol-2-ylidene]dipalladium(II), Dichloro[9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene]palladium(II), Dichloro(norbornadiene)palladium(II), Methanesulfonato[2,2′-bis(diphenylphosphino)-1,1′-binaphthyl](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato[1,1′-bis(diphenylphosphino)ferrocene)](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato[4,6-bis(diphenylphosphino)phenoxazine](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato[2-bis(3,5-di(trifluoromethyl)phenylphosphino)-3,6-dimethoxy-2′,4′,6′-tri-i-propyl-1,1′-biphenyl](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(diadamantyl-n-butylphosphino)-2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato[2-(di-1-adamantylphosphino)-3,6-dimethoxy-2′,4′,6′-tri-i-propyl-1,1′-biphenyl](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato[di-t-butyl(n-butyl)phosphine](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(di-t-butylneopentylphosphine)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato[2-(di-t-butylphosphino)-2′-(N,N-dimethylamino)-1,1′-biphenyl](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-(di-t-butylphosphino)-3,6-dimethoxy-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-(di-t-butylphosphino)-3-methoxy-6-methyl-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-di-t-butylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-di-t-butylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-methylamino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-2′,6′-bis(dimethylamino)-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-methylamino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-3,6-dimethoxy-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-3,6-dimethoxy-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-methylamino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato[2-(dicyclohexylphosphino)-2′-(N,N-dimethylamino)-1,1′-biphenyl](2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl)(2′-methylamino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato{(R)-(−)-1-[(S)-2-(dicyclohexylphosphino)ferrocenyl]ethyldi-t-butylphosphine}(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(2-dicyclohexylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-methylamino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato{[4-(N,N-dimethylamino)phenyl]di-t-butylphosphino}(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato[9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene][2′-amino-1,1′-biphenyl]palladium(II), Methanesulfonato[9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene](2′-methylamino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(tri-t-butylphosphino)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(tri-t-butylphosphino)(2′-methylamino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(tricyclohexylphosphine)(2′-amino-1,1′-biphenyl-2-yl)palladium(II), Methanesulfonato(tricyclohexylphosphino)(2′-methylamino-1,1′-biphenyl-2-yl)palladium(II), (2′-Methylamino-1,1′-biphenyl-2-yl)methanesulfonatopalladium(II) dimer, Tris{tris[3,5-bis(trifluoromethyl)phenyl]phosphine}palladium(0), chloro(η 2 -P,C-tris(2,4-di-tert-butylphenyl)phosphite)(tricyclohexylphosphine)palladium(II), 2-(2′-di-tert-butylphosphine)biphenylpalladium(II) acetate, di-μ-chlorobis[5-chloro-2-[(4-chlorophenyl)(hydroxyimino-kN)methyl]phenyl-kC]palladium dimer, di-μ-chlorobis[5-hydroxy-2-[1-(hydroxyimino-kN)ethyl]phenyl-KC]palladium(II) dimer, dicyclohexyl[9-(3-phenylpropyl)-9-fluorenyl]phosphonium tetrafluoroborate, dicyclohexyl-{2-sulfo-9-[3-(4-sulfo-phenyl)propyl]-9-fluorenyl}phosphonium-hydrogensulfate, 2′-(dimethylamino)-2-biphenylyl-palladium(II) chloride dinorbornylphosphine complex, 2-(dimethylaminomethyl)ferrocen-1-yl-palladium(II) chloride dinorbornylphosphine, a cyclopalladated 2-aminobiphenylmesylate, a Bedford catalyst, a Nájera catalyst, a Pd nanoparticle catalyst, NiCl 2 (dtbpy), chloro(2-methylphenyl)bis(triphenylphosphine)nickel(II), [1,2-bis(diphenylphosphino)ethane]dichloronickel(II), Ni(acac) 2 , NiCl 2 (PCy 3 ) 2 , Ni(1,5-COD) 2 , NiCl 2 dimethoxyethane, NiCl 2 -glyme, NiCl 2 , NiCl 2 (dppf), NiCl 2 (dppe), Bis(cyclopentadienyl)nickel(II), 2,3-Bis(2,6-diisopropylphenylimino)butane nickel(II) dibromide, Bis[(2-dimethylamino)phenyl]amine nickel(II) chloride, Bis(isopropylcyclopentadienyl)nickel, Bis(methylcyclopentadienyl)nickel(II), N,N′-Bis(salicylidene)ethylenediaminonickel(II), Bis(triphenylphosphine)nickel(II) dichloride, Chloro(cyclopentadienyl)(triphenylphosphine)nickel(II), Chloro(ethylcyclopentadienyl)(triphenylphosphinenickel(II), Chloro(2-methylphenyl)bis(triphenylphosphine)nickel(II), Chloro(1-naphthyl)bis(triphenylphosphine)nickel(II), Dibromobis(tributylphosphine)nickel(II), Dibromobis(triphenylphosphine)nickel(II), Dichlorobis(tributylphosphine)nickel(II), Dichlorobis(trimethylphosphine)nickel(II), methallylnickel chloride dimer, Hexaamminenickel(II) bromide, Nickel(II) acetate, Nickel(II) acetylacetonate, Nickel(II) bis(trifluoromethanesulfonimide), Nickel(II) bromide, Nickel(II) hexafluoroacetylacetonate, Nickel(II) trifluoromethanesulfonate, Tetrakis(triphenylphosphite)nickel(0), Trovitch Ni-Precatalyst and NiCl 2 (dppp).

6. The method of claim 1 , wherein the second transition metal catalyst is a Ru catalyst comprising a Ru atom.

7. The method of claim 1 , wherein the second transition metal catalyst is an Ir catalyst comprising an Ir atom.

8. The method of claim 1 , wherein the second transition metal catalyst is selected from the group consisting of Ru(bpy) 3 Cl 2 , Ru(bpm) 3 (PF 6 ) 2 , Ru(bpz) 3 (PF 6 ) 2 , Ru(bpy) 3 (PF 6 ) 2 Ru(menbpy) 3 (PF 6 ) 2 Ru(bpm) 3 (PF 6 ) 2 , Ru(phen) 3 (PF 6 ) 2 Ir[dF(CF 3 )ppy] 2 (bpy)PF 6 , Ir[dF(Me)ppy] 2 (dtbpy)PF 6 , Ir[dF(CF 3 )ppy] 2 (dtbpy)PF 6 , Ir(ppy) 2 (dtbpy)PF 6 , Ir(ppy) 3 , Ir[p-F(t-Bu)ppy] 3 , Ir(dFppy) 3 and Ir(Fppy) 3 .

9. The method of claim 1 , wherein the second transition metal catalyst is a Cu catalyst comprising a Cu atom.

10. The method of claim 2 , wherein the compound of Formula (A) has the structure:

wherein:

R 1A and R 1B are each independently hydrogen, an optionally substituted C 1-30 alkyl or an optionally substituted C 3-10 cycloalkyl, or OR 1A , OR 1B and the boron atom to which they attach are taken together to form an optionally substituted heterocyclyl;

each R 1C is independently hydrogen, an optionally substituted C 1-30 alkyl or an optionally substituted C 3-10 cycloalkyl;

R 2A and R 2B are each independently hydrogen or an optionally substituted C 1-30 alkyl, or OR 2A , OR 2B and the boron atom to which they attach can be taken together to form an optionally substituted heterocyclyl;

R 3A and R 3B are each independently an optionally substituted C 1-30 alkyl, an optionally substituted C 3-10 cycloalkyl, an amine, an arylamine, or an alkylamine, or R 3A , R 3B and the boron atom to which they attach are taken together to form an optionally substituted heterocyclyl;

R 4A and R 4B are each independently an optionally substituted C 1-30 alkyl, an optionally substituted C 3-10 cycloalkyl, an amine, an arylamine, or an alkylamine, or R 4A , R 4B and the boron atom to which they attach are taken together to form an optionally substituted heterocyclyl; and

R 5A and R 5B are each independently an optionally substituted C 1-30 alkyl, an optionally substituted C 3-10 cycloalkyl, an amine, an arylamine, or an alkylamine, or R 5A , R 5B and the boron atom to which they attach are taken together to form an optionally substituted heterocyclyl;

Q 1 is an optionally substituted monocyclic or bicyclic heteroaryl or an optionally substituted monocyclic or bicyclic heterocyclyl including 0 to 4 heteroatom moieties selected from —N═, —N(R 2B )—,

—O— and —S—;

wherein each R 2B is selected from the group consisting of D (deuterium), hydroxy, C 1-4 alkoxy, C 1-4 alkyl, C 3-10 cycloalkyl, aryl, heteroaryl, C 1-6 haloalkyl, alkenyl, alkynyl, cycloalkenyl, aryl(alkyl), heteroaryl(alkyl), heterocyclyl(alkyl), acyl, sulfenyl, sulfinyl, sulfonyl, an amino, a mono-substituted amino group or a di-substituted amino group;

each R 11 and each R 12 is independently selected from the group consisting of D (deuterium), halogen, hydroxy, C 1-4 alkoxy, C 1-4 alkyl, C 3-10 cycloalkyl, an optionally substituted C 3-10 cycloalkenyl, aryl, heteroaryl, C 1-6 haloalkyl, cyano, alkenyl, alkynyl, cycloalkenyl, aryl(alkyl), heteroaryl(alkyl), heterocyclyl(alkyl), acyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-thioamido, N-thioamido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, sulfenyl, sulfinyl, sulfonyl, haloalkoxy, an amino, a mono-substituted amino group or a di-substituted amino group; and

each n is independently an integer from 0 to 4.

11. The method of claim 2 , wherein the compound of Formula (A) is selected from the group consisting of:

12. The method of claim 1 , wherein said reacting is in the presence of a ligand.

13. The method of claim 12 , wherein the ligand is selected from the group consisting of A-caPhos, a-taPhos, Binap, BIPHEP, BippyPhos, Ad-BrettPhos, ditBuBrettPhos, BrettPhos, CataCXcium POMeCy, CataCXcium PtB, CataCXium PiCy, CataCXium FBn, CataCXium PCy, CataCXium PInCy, CataCXium POMetB, CataXCium A, CataXCium ABn, CataXCium AHI, CataXCium C, CataXCium FBu, CataXCium FPrPh, CataXCium FSulf, CataXCium PIntB, CPhos, Cy-BIPHEP, Cy-BippyPhos, Cy-JohnPhos, Cy-PhenCarPhos, DavePhos, DCEPhos, DCyPF, DiPPF, di-tBu-neopentylPhosphonium HBF 4 , DPEPhos, DPPBz, DPPE, DPPF, DtBPF, DTP-DPEPhos, JackiePhos, JohnPhos, Me4XPhos, Me4t-BuXPhos, MeDalPhos, MePhos, MorDalPhos, N-dicyclohexylphosphino-2-(2′-methylphenyl)-1H-indole, XantPhos, PCy 3 HBF 4 , P(o-OMePh) 3 , PPh 3 , PtBu 3 HBF 4 , PXy 3 , QPhos, PhDavePhos, RockPhos, RuPhos, SL-J003-1, SL-J009-1, SPhos, SPhos-SO 3 Na, SymPhos, tBuBiNap, tBuDavePhos, tBuMePhos, tBuXantPhos, tBuXPhos, TrixiePhos, XantPhos, XPhos, XPhos-SO 3 Na, Me 3 P HBF 4 , Et 3 P HBF 4 , xylBinap, Cy-cBRIDP, AmindolePhos, NPCy o-Andole-Phos, NPCy Phendole-Phos, cBRIDP, vBRIDP, CyvBRIDP, CM-Phos, KitPhos, 4,4′-di-tert-butyl-2,2′-dipyridyl, 2,2′-bipyridyl, 4,4′-dimethoxy-2,2′-bipyridyl, 2,2′-biquinoline, bathophenanthroline, s-BuPyBox, neocuproine, trans-2-aminocyclohexanol, and combinations thereof.

14. The method of claim 1 , wherein said reacting is in the presence of a precatalyst.

15. The method of claim 14 , wherein the precatalyst is selected from the group consisting of XantPhos 3rd gen, tBuXPhos 3rd gen, CPhos 3rd gen, APhos 3rd gen, phosphaadamantane 3rd gen, XPhos 3rd gen, RuPhos 3rd gen, JackiePhos 3rd gen, 1st gen BrettPhos, 1st gen ditBuXPhos, 1st gen RuPhos, 1st gen SPhos, 1st gen XPhos, 2nd gen RuPhos, 2nd gen SPhos, 2nd gen XPhos, OMs Pd Dimer, and combinations thereof.

16. The method of claim 1 , wherein the base is selected from the group consisting of a metal hydroxide base, a metal carbonate base, a metal bicarbonate base, an amine base, a metal fluoride base, a metal alkoxide base, a metal carboxylate base and a metal phosphate base.

17. The method of claim 16 , wherein the base is selected from the group consisting of Et 3 N, Hunig's base, pyridine, piperidine, morpholine, 1,8-Bis(dimethylamino)naphthalene, DBU, Na 2 CO 3 , K 2 CO 3 , Li 2 CO 3 , Cs 2 CO 3 , KOtBu, K 2 HPO 4 , Na 2 HPO 4 , Na 3 PO 4 , K 3 PO 4 , NaOH, KOH, CsOH, LiOH, KF, CsF, NaOAc, KOAc, CsOAc, LiOAc, LiOtBu, NaOtBu, NaHCO 3 , KHCO 3 , CsHCO 3 , and LiHCO 3 .

18. The method of claim 1 , wherein M is selected from the group consisting of Li + , Na + , K + , Rb + , Cs + , a quaternary nitrogen, Mg +2 , Ca +2 , Sr +2 , and Ba +2 .

19. The method of claim 1 , wherein said reacting is in the presence of visible light.

20. A compound selected from the group consisting of Formula (Ala), Formula (A1b), Formula (A1c) and Formula (A1d):

wherein R 1 is selected from the group consisting of an optionally substituted C 1-30 alkyl, an optionally substituted C 2-30 alkenyl, an optionally substituted C 3-10 monocyclic cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, a halogen, an optionally substituted C-carboxy, an amino, a mono-substituted amino, a di-substituted amino, an optionally substituted C-amido, an optionally substituted N-amido, an optionally substituted C 1-30 alkoxy, a hydroxy, an optionally substituted C 1-30 haloalkyl, a cyano, an optionally substituted S-sulfonamido, an optionally substituted N-sulfonamido, an optionally substituted O-carboxy, an optionally substituted C 2-30 alkynyl, an optionally substituted C 3-10 cycloalkenyl, an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl), an optionally substituted acyl, an optionally substituted thiocarbonyl, an optionally substituted O-carbamyl, an optionally substituted N-carbamyl, an optionally substituted O-thiocarbamyl, an optionally substituted N-thiocarbamyl, an optionally substituted C-thioamido, an optionally substituted N-thioamido, an optionally substituted sulfenyl, an optionally substituted sulfinyl, an optionally substituted sulfonyl, an optionally substituted haloalkoxy, and a first boron-containing moiety, wherein the first boron-containing moiety is connected by the boron.

21. The compound of claim 20 selected from the group consisting of:

22. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt of any of the foregoing.

Assignments (3)
CHANGE OF NAME Recorded Jan 3, 2020
From: ZENO ROYALTIES & MILESTONES, LLC
To: RECURIUM IP HOLDINGS, LLC
Reel/Frame 051477/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2019
From: PINCHMAN, JOSEPH ROBERT; HOPKINS, CHAD DANIEL; BUNKER, KEVIN DUANE; HUANG, PETER QINHUA
To: KALYRA PHARMACEUTICALS, INC.
Reel/Frame 049017/0064 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2019
From: KALYRA PHARMACEUTICALS, INC.
To: ZENO ROYALTIES & MILESTONES, LLC
Reel/Frame 049017/0077 →
Continuity (2)
Provisional Application 62378453 · Aug 23, 2016
Related Publication 20190202769A1 · Jul 4, 2019